On November 15, 2021, we and Valo Health mutually agreed to terminate the proposed initial Business Combination based on market conditions, particularly in the biotechnology area. As such, we continue to search for a potential initial Business Combination target. The PIPE I Investment and PIPE II Investment were also both terminated upon the termination of the proposed initial Business Combination with Valo Health.
Results of Operations and Known Trends or Future Events
We have neither engaged in any operations (other than searching for a Business Combination after our IPO) nor generated any revenues to date. Our only activities through September 30, 2022 were organizational activities and those necessary to prepare for the IPO and the proposed initial Business Combination. We do not expect to generate any operating revenues until after the completion of our Business Combination. We expect to generate non-operating income in the form of interest income on marketable securities held after the IPO. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.
For the three months ended September 30, 2022, we had a loss from operations of $578,988, which consisted of $528,988 of general and administrative expenses and $50,000 in franchise tax expense. Of the $528,988 of general and administrative expenses, $167,358 was related to the amortization of Directors’ and Officers’ liability insurance, $231,189 was related to legal expense and $130,441 was related to other professional services. We also incurred a $1,560,060 gain on marketable securities held in Trust Account and $317,113 in income tax expense, resulting in net income of $663,959 for the three months ended September 30, 2022.
For the three months ended September 30, 2021, we had a loss from operations of $898,503, which consisted of $848,503 of general and administrative expenses and $50,000 in franchise tax expense. Of the $848,503 of general and administrative expenses, $167,358 was related to the amortization of Directors’ and Officers’ liability insurance, $512,781 was related to legal expense and $168,364 was related to other professional services. We also incurred a $1,750,000 gain on the change in fair value of derivative liabilities, and a $5,301 gain on marketable securities held in Trust Account, resulting in a net income of $856,798 for the three months ended September 30, 2021.
For the nine months ended September 30, 2022, we had a loss from operations of $1,394,343, which consisted of $1,244,343 of general and administrative expenses, and $150,000 in franchise tax expenses. Of the $1,244,343 of general and administrative expenses, $496,617 was related to the amortization of Directors’ and Officers’ liability insurance, $263,221 was related to legal expense and $484,505 was related to other professional services. We also incurred a $150,000 gain on the change in fair value of derivative liabilities, a $2,078,237 gain on marketable securities held in Trust Account and $366,506 in income tax expense, resulting in net income of $467,388 for the nine months ended September 30, 2022.
For the period from January 15, 2021 (inception) through September 30, 2021, we had a loss from operations of $3,267,946, which consisted of $30,000 in formation costs, $3,087,946 in general and administrative expenses, and $150,000 in franchise tax expenses. Of the $3,087,946 of general and administrative expenses, $383,832 was related to the amortization of Directors’ and Officers’ liability insurance, $2,272,115 was related to legal expense and $431,999 was related to other professional services. We also incurred $12,137,500 in financing expenses on derivative classified instrument, offset by the change in fair value of derivative liabilities of $11,600,000, and a $10,545 gain on marketable securities held in Trust Account resulting in a net loss of $3,794,901 for the period from January 15, 2021 (inception) through September 30, 2021.
Liquidity and Capital Resources
As of September 30, 2022, the Company had $0 in its operating bank account, $296,018 in prepaid expenses, $347,095,266 in marketable securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem its common stock in connection therewith and a working capital deficit of $4,987,048. As of September 30, 2022, $2,095,266 of the amount on deposit in the Trust Account represented interest income, which is available for payment of franchise taxes and expenses in connection with the liquidation of the Trust Account. In addition, the Working Capital Loan and advances from related parties are available to the Company to fund operations.
If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.
23